Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China

May 24, 2010

BEIJING, May 24 /PRNewswire-Asia-FirstCall/ — Dehaier Medical Systems Ltd.
(Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and
sale of medical products in China, announced today an exclusive distributor
agreement for HEYER Medical’s Cumulus ultrasonic nebulizer in China. Dehaier
is authorized to distribute all models of this product.

HEYER Cumulus is suitable for the treatment of respiratory tract
conditions such as asthma, bronchitis, chronic respiratory infections and
others. The unit can be used for all aspects of respiratory treatment and air
humidification. With a full range of accessories, the Cumulus Nebulizer is
tailored for optimum application in hospitals, surgeries and at home.

HEYER Cumulus is designed to be extremely easy to clean. All application
parts and the ultrasonic cup can be dismantled in seconds. In addition, all
parts (including the ultrasonic cup assembly) that may be subject to patient
contamination can be easily disinfected or autoclaved.

Mr. Volker Muller, General Manager of HEYER Medical (Beijing) Ltd., said,
“We are very pleased that Dehaier will represent HEYER products in China.
Dehaier is a premier medical device company that has a powerful distribution
network in China. We believe this exclusive distribution agreement is an
excellent business expansion opportunity for both companies.”

Mr. Ping Chen, Dehaier’s Chief Executive Officer, said, “Our new
partnership with HEYER Medical further supplements our product line for
treatment of respiratory diseases. This not only provides Dehaier with
additional highly sophisticated products, but also widens the experience of
our marketing and service teams. This exclusive agreement provides us with
access to the market segment in China for nebulizer products, which we
estimate to be about $30 million per year. The Cumulus is an ideal product
addition to our Homecare Medical Products segment that already includes
homecare ventilators, oxygen generators, sleep screening systems and our
Dehaier rhinitis hyperthermia device.

“We estimate that on a global basis, the fast growing market for
respiratory and oxygen homecare products is in excess of $2.0 billion per
year,” Chen said.

About HEYER Medical AG

HEYER was founded in 1883 in Germany and has become an innovator in
inhalation technology for the treatment of respiratory tract diseases. Today
HEYER is an internationally acknowledged specialist in state-of-the-art
inhalation and anesthesia medical equipment, oxygen concentrators, breathing
therapy equipment and connecting equipment. HEYER products are used all over
the world, particularly in the medical field, in clinics and practices in
Europe and Asia as well as in the Middle East, South America and the USA. Our
inhalation equipment is also increasingly used in wellness applications and
for treatment and care at home. Website http://www.heyermedical.de

About Dehaier Medical Systems Ltd.

Dehaier Medical Systems is an emerging leader in the development, assembly,
marketing and sale of medical products in China, including respiratory and
oxygen homecare products. The company develops and assembles its own branded
products from third party components. The company also distributes products
designed and manufactured by other companies including medical devices and
respiratory and oxygen homecare products from IMD (Italy), Timesco (UK),
ResMed (Australia), Welch Allyn (USA), HEYER (Germany) and JMS (Japan).
Dehaier’s technology is based on two patents, five pending patents and
proprietary technology. More information may be found at
http://www.chinadhr.com .

Information for investors, including an investment profile about Dehaier
is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online
investor kit including press releases, current price quotes, stock charts and
other valuable information for investors is available at
http://www.hawkassociates.com .

Forward-looking Statements

This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other statements that
are other than statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and service
demand and acceptance, changes in technology, economic conditions, the impact
of competition and pricing, government regulation, and other risks contained
in reports filed by the company with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and whether made
by or on behalf of the company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany the
forward-looking statements. In addition, the company disclaims any obligation
to update any forward-looking statements to reflect events or circumstances
after the date hereof.

    For more information, please contact:

    Investor contact:

     Hawk Associates
     Julie Marshall or Frank Hawkins
     Tel:   +1-305-451-1888
     Email: dehaier@hawkassociates.com

SOURCE Dehaier Medical Systems Ltd.

Source: newswire

comments powered by Disqus